Navigation Links
hNT BlueNeurons Express b-Galactosidase at High ,Levels

hNT BlueNeurons are ideal for use in transplantation studies

hNT BlueNeurons Express b-Galactosidase at High Levels


Michael McGrogan * Guadalupe Gonzalez * Waldemar Lernhardt
Layton BioScience, Inc. Gilroy, California


Stratagene's hNT BlueNeurons express beta-galactosidase at high levels and are derived from a clone of the NT2 teratocarcinoma stably transfected with a lacZ gene expression vector. Because they are easily distinguished from surrounding tissue by in situ staining for beta-galactosidase, hNT BlueNeurons are ideal for use in transplantation studies.

figure 1

The NT2 cell line, derived from a human teratocarcinoma, exhibits properties indicative of a committed neuronal precursor stage. NT2 cells can be induced by retinoic acid (RA) to differentiate in vitro into postmitotic central nervous system (CNS) neurons, hNT neurons* (figure 1). In the course of RAinduced differentiation, NT2 cells lose neuroepithelial markers and telomerase activity, acquire many neuronal markers, begin to express glutamate receptor channels, change the metabolism of amyloid precursor proteins and become permissive for infection by the human immunodeficiency virus (HIV).

An increasing number of reports describe transplantation of hNT neurons into rodent brains.15 hNT neurons successfully integrate into surrounding tissue and establish synapses. Although hNT neurons can be identified in transplanted tissue by staining with antibodies specific for human markers, an additional method of identification would allow immunostaining for multiple markers. The lacZ gene was chosen as a marker to be introduced into hNT neurons because it is very
'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. An Epitope Tagging Vector for Gene Expression in Mammalian Cells
2. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
3. High-Level Expression of Peanut Allergens Affected by Rare Codon Usage
4. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
5. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
6. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
7. Functional Cloning Using ViraPort Retroviral cDNA Expression Libraries
8. High-Level Protein Expression, One-Column Purification, and FLAG Epitope Tagging in E. coli
9. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
10. A New Lambda Vector for Mammalian Expression
11. Expression and Purification of Recombinant Proteins That Have Native Amino Acid Sequence
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: hNT BlueNeurons Express Galactosidase High Levels

(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... 30, 2015 Biodata, producer of ... integrated protocols and specimen management systems, and ChemAxon, ... consulting services for life science research, announce their ... newest feature: chemical structure and reaction support. Already ... biologists, bio-chemists, and more, the integration of ChemAxon's ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Agence de Medecine,Preventive (AMP) announced today the appointment ... SIVAC (Supporting Independent Immunization and,Vaccine Advisory Committees) initiative. ... national immunization technical advisory groups in six,resource poor ... committees will help,national health authorities to set up ...
... 12 Synvista Therapeutics, Inc. (NYSE Alternext ... BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of ... the effect of alagebrium on exercise tolerance in patients with ... enrollment of its BREAK ( B eginning a R ...
... ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) and ... a definitive agreement for Abbott to acquire AMO for $22 ... $2.8 billion, inclusive,of estimated net debt at the time of ... leader in ophthalmic care, comprised of three segments: cataract,surgery, laser ...
Cached Biology Technology:French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... University previously developed ion transistors for transport of both ... has now succeeded in combining both transistor types into ... electronics. An advantage of chemical circuits is ... various functions. This means that we now have new ...
... diseases, the St. Jude Children,s Research Hospital Washington ... release of comprehensive human cancer genome data for free ... information released more than doubles the volume of high-coverage, ... sources combined. This information is valuable not just to ...
... collaboration between scientists from the Experimental Therapeutics Centre (ETC) under ... from Tan Tock Seng Hospital (TTSH) has enabled the successful ... test kit available to date. With this highly advanced kit, ... H5N1 viruses in a single test with almost 100% accuracy, ...
Cached Biology News:World's largest release of comprehensive human cancer genome data helps speed discoveries 2World's largest release of comprehensive human cancer genome data helps speed discoveries 3Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 2Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 3